These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 15221296)
1. 99mTc-depreotide scintigraphy of bone lesions in patients with lung cancer. Mena E; Camacho V; Estorch M; Fuertes J; Flotats A; Carrió I Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1399-404. PubMed ID: 15221296 [TBL] [Abstract][Full Text] [Related]
2. Role of scintigraphy with technetium-99m depreotide in the diagnosis and management of patients with suspected lung cancer. Axelsson R; Herlin G; Bååth M; Aspelin P; Kölbeck KG Acta Radiol; 2008 Apr; 49(3):295-302. PubMed ID: 18365818 [TBL] [Abstract][Full Text] [Related]
3. 99mTc depreotide scan compared with 99mTc-MDP bone scintigraphy for the detection of bone metastases and prediction of response to hormonal treatment in patients with breast cancer. Van Den Bossche B; D'haeninck E; De Winter F; Van Belle S; Dierckx RA; Van De Wiele C Nucl Med Commun; 2004 Aug; 25(8):787-92. PubMed ID: 15266172 [TBL] [Abstract][Full Text] [Related]
4. Imaging of regional lymph node metastases with 99mTc-depreotide in patients with lung cancer. Danielsson R; Bååth M; Svensson L; Forslöv U; Kölbeck KG Eur J Nucl Med Mol Imaging; 2005 Aug; 32(8):925-31. PubMed ID: 15841374 [TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor scintigraphy with 99mTc-Depreotide (NeoSpect) in discriminating between malignant and benign lesions in the diagnosis of lung cancer: a pilot study. Bååth M; Kölbeck KG; Danielsson R Acta Radiol; 2004 Dec; 45(8):833-9. PubMed ID: 15690613 [TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of 99mTc-depreotide and 99mTc-EDDA/HYNIC-TOC thorax scintigrams acquired for the purpose of differential diagnosis of solitary pulmonary nodules. Płachcińska A; Mikołajczak R; Kozak J; Rzeszutek K; Kuśmierek J Nucl Med Rev Cent East Eur; 2006; 9(1):24-9. PubMed ID: 16791800 [TBL] [Abstract][Full Text] [Related]
7. Quantitative assessment of 99mTc-depreotide uptake in patients with non-small-cell lung cancer: immunohistochemical correlations. Herlin G; Kölbeck KG; Menzel PL; Svensson L; Aspelin P; Capitanio A; Axelsson R Acta Radiol; 2009 Oct; 50(8):902-8. PubMed ID: 19707908 [TBL] [Abstract][Full Text] [Related]
8. 99mTc-depreotide scintigraphy in the evaluation of indeterminate pulmonary lesions: clinical experience. Martins T; Lino JS; Ramos S; Oliveira L Cancer Biother Radiopharm; 2004 Apr; 19(2):253-9. PubMed ID: 15186606 [TBL] [Abstract][Full Text] [Related]
9. [Fusion of pulmonary scintigraphy with Tc99m-depreotide imaging with CT scan in recognizing solitary pulmonary nodule]. Szaluś N; Chciałowski A; From S; Zagrodzka M; Pietrzykowski J; Dziuk E Pol Merkur Lekarski; 2008 Oct; 25(148):330-4. PubMed ID: 19145931 [TBL] [Abstract][Full Text] [Related]
10. 99mTc-depreotide in the evaluation of bone infection and inflammation. Papathanasiou ND; Rondogianni PE; Pianou NK; Karampina PA; Vlontzou EA; Datseris IE Nucl Med Commun; 2008 Mar; 29(3):239-46. PubMed ID: 18349794 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of Tc-99m depreotide scintigraphy in the evaluation of solitary pulmonary nodules. Grewal RK; Dadparvar S; Yu JQ; Babaria CJ; Cavanaugh T; Sherman M; Jacobstein J Cancer J; 2002; 8(5):400-4. PubMed ID: 12416898 [TBL] [Abstract][Full Text] [Related]
12. Diagnosis and staging of children's lymphoma using the technetium-labelled somatostatin analogue, 99mTc-depreotide. Cholewinski W; Kowalczyk JR; Stefaniak B; Stefaniak J; Poniatowicz-Frasunek E; Tarkowska A Eur J Nucl Med Mol Imaging; 2004 Jun; 31(6):820-4. PubMed ID: 14762697 [TBL] [Abstract][Full Text] [Related]
13. Efficiency of 18F-FDG and 99mTc-depreotide SPECT in the diagnosis of malignancy of solitary pulmonary nodules. Halley A; Hugentobler A; Icard P; Porret E; Sobrio F; Lerochais JP; Bouvard G; Zalcman G; Agostini D Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1026-32. PubMed ID: 15877227 [TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of 99mTc-depreotide and 201Tl chloride single photon emission tomography in the characterization of pulmonary lesions. Boundas D; Karatzas N; Moralidis E; Arsos G; Drevelengas A; Pistevou-Gompaki K; Karakatsanis C Nucl Med Commun; 2007 Jul; 28(7):533-40. PubMed ID: 17538394 [TBL] [Abstract][Full Text] [Related]
15. Early prediction of endocrine therapy effect in advanced breast cancer patients using 99mTc-depreotide scintigraphy. Van Den Bossche B; Van Belle S; De Winter F; Signore A; Van de Wiele C J Nucl Med; 2006 Jan; 47(1):6-13. PubMed ID: 16391181 [TBL] [Abstract][Full Text] [Related]
16. Bone metastases and lung cancer recurrence on (99m)Tc-depreotide imaging. Meristoudis G; Ilias I; Batsakis C; Christakopoulou J Hell J Nucl Med; 2008; 11(3):185-6, author reply 186. PubMed ID: 19081868 [No Abstract] [Full Text] [Related]
17. 99mTc-depreotide scintigraphy versus 18F-FDG-PET in the diagnosis of radioiodine-negative thyroid cancer. Rodrigues M; Li S; Gabriel M; Heute D; Greifeneder M; Virgolini I J Clin Endocrinol Metab; 2006 Oct; 91(10):3997-4000. PubMed ID: 16895961 [TBL] [Abstract][Full Text] [Related]
18. 99mTc-depreotide tumour uptake in patients with non-Hodgkin's lymphoma. Bushnell DL; Menda Y; Madsen MT; Link BK; Kahn D; Truhlar SM; Juweid M; Shannon M; Murguia JS Nucl Med Commun; 2004 Aug; 25(8):839-43. PubMed ID: 15266180 [TBL] [Abstract][Full Text] [Related]
19. Uptake of depreotide in a patient with lung cancer and bone metastases. Gao Z; Biersack HJ; Bucerius J Clin Nucl Med; 2005 Jan; 30(1):60-1. PubMed ID: 15604979 [No Abstract] [Full Text] [Related]
20. Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma. Lind P; Gallowitsch HJ; Langsteger W; Kresnik E; Mikosch P; Gomez I J Nucl Med; 1997 Mar; 38(3):348-52. PubMed ID: 9074515 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]